Bone Microarchitecture Evaluation by HR-pQCT in Youngs Who Developed AN in Peri or Prepubertal Period. (AMOS)
Monocentric Study Evaluating Bone Microarchitecture by High Resolution Quantitative Computerized Tomography (HR-pQCT) in Young Adults and Adolescents Who Developed Anorexia Nervosa (AN) in Peri or Prepubertal Period.
The occurrence of anorexia nervosa (AN) during childhood or adolescence rapidly induces starvation, stop of growth and impaired mineralization of bone tissue together with an interruption of pubertal development. These consequences are initially reversible following food intake return but can lead to a more irreversible status with low height, osteoporosis and high fracture risk. The onset of the disease more and more early in life, with the first stages of puberty suggest that these consequences will be even more severe as bone resistance will be damaged by more profound effects on bone growth as well. It is therefore critical to evaluate these bone metabolism alterations in order to better manage these patients.
At every age and in every clinical circumstance either physiologic or pathologic, high resolution peripheral quantitative computerized tomography (HRpQCT) provides an evaluation of bone microarchitecture that is more informative than the global quantitative assessment given by conventional Dual Energy X-ray Absorptiometry) DEXA, with a better estimate of clinical fracture risk.
Here, we propose to measure cortical parameters, such as cortical thickness which plays a key role in bone biomechanical strength in young adults aged between 20 and 30 years-old, who had developed AN as early as the during the first stages of puberty but no longer present, compared to age-and sex-matched healthy volunteers. Other micro-architectural parameters will also be studied. In an exploratory phase, we will evaluate these bone microarchitectural parameters together with bone biological turnover markers and markers of sexual maturation in adolescents or young adults 20 years-old or less, undernourished and currently managed for AN.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Saint-etienne、法国、42000
- CHU de Saint-Etienne
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Patients over 20 years old:
- Age > 20 and < 30 years old
- Patients managed for AN in the pediatric or endocrinology of the university hospital of St-Etienne
- Patients who developed AN as early as the during the first stages of puberty defined by Tanner stage 1 to 4, with a diagnosis of AN based on DSM-IV current criteria:
- Weight loss : deny of maintaining body weight over minimal normal threshold (85 % age and height matched)
- Intense fear of gaining weight or becoming obese despite weight insufficiency;
- Impaired perception of weight or dysmorphophobia;
- Excessive role of weight or body shape in self-esteem or deny of current leanness;
- Secondary amenorrhea during 3 or more menstrual cycles in young girls or primary amenorrhea
- Duration of AN of at least 6 months
- BMI >85% of theoretical BMI (efficient renutrition)
Patients less than 20 years old :
- Age > 10 and < 20 years old
- Patients managed for AN in the pediatric or endocrinology of the university hospital of St-Etienne
- Patients who developed AN as early as the during the first stages of puberty defined by Tanner stage 1 to 4, with a diagnosis of AN based on DSM-IV current criteria:
- Weight loss : deny of maintaining body weight over minimal normal threshold (85 % age and height matched)
- Intense fear of gaining weight or becoming obese despite weight insufficiency;
- Impaired perception of weight or dysmorphophobia;
- Excessive role of weight or body shape in self-esteem or deny of current leanness;
- Secondary amenorrhea during 3 or more menstrual cycles in young girls or primary amenorrhea
- Duration of AN of at least 6 months
Exclusion Criteria:
- Renal insufficiency
- Cushing
- Dysthyroidism
- Inflammatory disease
- Pregnancy
- Lack of consent
- Subject under legal protection
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Patients 20 - 30 years-old
HR-pQCT and DEXA for measure bone quality and quantity
|
The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
其他名称:
The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min).
It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
|
|
实验性的:Patients 10 - 20 years-old
Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
|
The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
其他名称:
The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min).
It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cortical thickness
大体时间:Day 1
|
Cortical thickness (in mm) is a composite outcome measured with HR pQCTon 3D images of distal radius and distal tibia.
|
Day 1
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of patients with bone degradation
大体时间:Day 1
|
Bone degradation is a composite outcome measured by cortical and architectural parameters measured with HR pQCTon 3D images of distal radius and distal tibia.
The parameters are : Total volumetric bone mineral density (mg/ccm HA), Trabecular volumetric bone mineral density (mg/ccm HA), Cortical volumetric bone mineral density (mg/ccm HA), Number of bone trabeculae (1/mm), Trabecular thickness (mm) Cortical thickness (mm), Trabecular spacing (mm), Trabecular distribution (mm)
|
Day 1
|
|
number of patients with osteoporosis
大体时间:Day 1
|
Osteoporosis is measured with DEXA.
DEXA measure the Bone Mineral Density (g/cm2)
|
Day 1
|
|
Clinical and biological phenotype of AN patients 20 years-old or less
大体时间:Day 1
|
Clinical and biological phenotype of AN patients 20 years-old or less is a composite factor : Pubertal stage at disease onset, Duration of AN, Height shortening compared to optimal genetically defined height, Serum levels of FGF23, Serum levels of IGF 1, Serum levels of sexual steroids (FSH, LH, oestradiol, testosterone, SeBG, AMH, inhibin B), Serum levels of bone formation and resorption markers (cross laps, osteocalcin, total alkaline phosphatases), Serum levels of leptin, Bone mineral density measured by DXA
|
Day 1
|
合作者和调查者
调查人员
- 首席研究员:Thierry THOMAS, MD PhD、CHU de Saint-Etienne
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.